“Un ramo industriale in forte crescita” – Intervista a Daniela Bührig, Executive Director di Farma industria Ticino 15 Marzo 2022
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. 4 Marzo 2022
Farma Industria Ticino incontra i Consiglieri di Stato Christian Vitta e Raffaele De Rosa 21 Febbraio 2022
Verity PharmaceuticalsTM and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico 18 Febbraio 2022
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes 14 Gennaio 2022
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements 21 Dicembre 2021
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQTM (infigratinib) in Canada 21 Dicembre 2021
Il 3° Rapporto di Sostenibilità conferma l’impegno di IBSA per il benessere delle Persone 20 Dicembre 2021
Linkedin